GlassScriptPhysician profile
Grigoriy Rapoport
NPI 1063807261
$1,443.28
in general payments reported to CMS, 2019-2025
16 companies · $35.30 in 2025
The $35.30 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.71 · 2022: $373 · 2023: $629 · 2024: $388 · 2025: $35.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $238.04 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.25 | 2022-2024 | Entyvio |
| Janssen Biotech, INC. | $167.04 | 2022-2024 | Stelara, Simponi Aria, Remicade |
| Celgene Corporation | $125.36 | 2023-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $111.10 | 2022-2024 | Ocaliva |
| Medtronic, INC. | $109.51 | 2023 | Endoflip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.90 | 2022-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $64.16 | 2022-2024 | Ibsrela |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
| Boston Scientific Corporation | $35.30 | 2025 | Speedband Superview Super 7 |
| Aimmune Therapeutics, INC. | $33.22 | 2024 | |
| Pfizer INC. | $32.70 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $24.08 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $18.89 | 2023 | Dificid |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $17.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigoriy Rapoport listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.